Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology (ASH) 2024 ...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug ...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase ...

We are pleased that the European Commission approved Ordspono or odronextamab, or CD20xCD3 bispecific for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, marking the ...

For example, MDX-1203, an anti-CD70 antibody conjugated via a peptide-based linker to a prodrug of CC ... cell carcinoma and relapsed/refractory B-cell non-Hodgkin's lymphoma last July.

Linker design should balance stability and release kinetics, while payloads should be potent and have minimal toxic side effects. Conjugation methods must ensure uniformity and stability of the ADC.

B-cell therapy (also called B-cell depletion therapy) is a treatment for people with multiple sclerosis (MS). It targets certain cells -- called B cells -- that can damage nerve fibers in your ...

B-cell therapy uses drugs called monoclonal antibodies to attack white blood cells known as B cells that cause nerve damage. The FDA has approved three such drugs for MS. Ocrelizumab (Ocrevus ...

Celltrion Inc. posted preclinical study results of two new antibody-drug conjugate (ADC) candidates – CT-P70 and CT-P71 – at the World ADC 2024 conference in San Diego Nov. 6, with plans to move the ...

After four failed rounds of chemotherapy for B cell lymphoma, the professional driver from Bishop's Stortford, Hertfordshire, had about two weeks left to live. She became one of the first patients ...